daily salt intake, which was estimated by the sodium and creatinine concentrations using Tanaka's formula. RESULTS: 1) 175 patients were in the NP group, and 148 patients were in the non-NP group. Patients who took three antihypertensives and diuretics were present at significant higher rate in the NP group than in the non-NP group(10.3% vs 4.1%, p[0.034 the chi-square test). We considered resistant hypertension might be related to NP. 2) Non-dipping BP were observed at significantly higher rate in the NP group than in the non-NP group (76.5% vs 41.2%, p [ 0.036 the chi-square test). The average daily salt intake was significantly higher in the NP group than in the non-NP group (9.43g/day vs 7.69 g/day, p[0.485 Wilcoxon rank sum test) (Graph).
INTRODUCTION AND OBJECTIVES: Male Stress Urinary
Incontinence (SUI) is a debilitating condition, resulting often from radical prostatectomies. Current treatments include bulking agents, urethral slings and artificial sphincters. However efficacy is inconsistent, especially in severe incontinence where bulking agents and conventional slings fail. Furthermore artificial sphincters involve major surgery. ATOMS (A.M.I., Austria) is a new adjustable sling consisting of a balloon mechanism inflated via a buried port-catheter allowing ongoing pressure adjustments in an outpatient setting, without needing anaesthetics. We present the first experience in the United Kingdom of using ATOMS in treating men who developed SUI post prostate surgery, including patients who have failed previous conventional SUI surgical treatment.
METHODS: Since 2015, 40 men (average age 70.4, range 50 -81) with SUI post-surgery underwent insertion of ATOMS under general anaesthetic. 37 (93%) developed stress incontinence following radical prostatectomy. Follow-up was for up to 3 years (average -17 months) via a specialist clinic.
RESULTS: 34/40 (85%) post ATOMS were dry (defined as using up to a maximum of one pad for reassurance only). 22/40 (55%) achieved dryness within 6 months (range 1 -24 months). 15 (44%) of these newly dry patients had previously failed other surgical incontinence treatments (Urethral Bulking agents, Trans-obturator Tapes). Average pad use (per day) decreased from 3.2 to 0.6. 18/34 (53%) of patients achieved dryness without needing any top-ups. 5 required 1 top up. 5 required 2 top ups. 6 required 4 top ups. 5/6 (83%) of the "non-dry" patients had previously received radiotherapy. However ATOMS still reduced pad usage by 72% in these post-radiotherapy patients.
Average pain levels 2-3 weeks post-op was 2.5 out of 10. This decreased to 0.5 out of 10 by 6-8 weeks. Complications were as follows: 2 patients developed superficial infections requiring antibiotics alone. 1 had erosion of inflator mechanism requiring reinsertion under general anaesthetics. 1 developed perineal pain requiring balloon deflation.
CONCLUSIONS: ATOMS is a novel safe and effective treatment for men with SUI post surgery, including radical prostatectomy, and also in patients where other surgical therapies have failed. Its efficacy is hindered by previous radiotherapy, but is still successful at reducing overall pad usage. Further studies on ATOMS in larger groups of patients with longer follow-ups are required to confirm these positive outcomes. In 2010 the second-generation AdVanceXP was introduced in Europe with highly useful changes in the sling configuration and needle design. In 2019 the AdVanceXP will be introduced also in the USA; Aim of this study was to evaluate the safety and effectiveness of the AdVance XP in a prospective multicentre long term follow-up study METHODS: 115 patients were included. Patients with previous urinary incontinence (UI) surgery, previous radiotherapy, nocturnal UI and a functional urethra < 1cm in the preoperative repositioning test were excluded. Postoperatively, a standardised 24-h pad test, qualityof-life scores [International Quality of Life score (IQOL) and International Consultation on Incontinence Questionnaire short form (ICIQ-UI SF)], visual analogue scale (VAS) for pain, five-item version of the International Index of Erectile Function (IIEF-5), International Prostate Symptom Score (IPSS) and Patient Global Impression of Improvement (PGI-I) score were carried out. The patient collective defined as "cured" were those patients with a pad test < 0-5 g. The patient group described as "improved" showed a reduction of urine loss of >50%. All others were classified as "failures". Significance analysis was performed using the Wilcoxon test.
RESULTS: The mean preoperative urine loss in the 24-h pad test was 341g (median 272.0 g). After a follow-up of 24 months (102 patients), 66.7% of the patients were cured and 26.5% had improved. The mean urine loss decreased significantly to 18.6 g (P < 0.001), with a mean VAS score of 0.3, and mean PGI-I of 1.5. After a followup of 48 months (60 patients), 71.7% of the patients were cured and 15.0% had improved. The mean urine loss decreased significantly to 24.4g (P < 0.001), with a mean VAS score of 0.1, and mean PGI-I of 1.4. The mean IQOL and ICIQ-UI SF improved significantly (both P < 0.001). After a follow-up of 60 months (36 patients), 61.1% of the patients were cured and 19.4% had improved. The mean urine loss decreased significantly to 24.2 g (P < 0.001), with a mean VAS score of 0.2, and mean PGI-I of 1.6. The mean IQOL and ICIQ-UI SF improved significantly (both P < 0.001) after 60 months. There were no significant postoperative changes in IIEF-5 and IPSS. No intraoperative and no long-term complications occurred. No erosion or explantation occurred. Due to a presumable intraoperative overcorrection of the sling during Repositioning or/and Tyvek-cover
